Off-Label Immunosuppressant Drugs in Solid Organ Transplantation

被引:0
|
作者
Nogueiras-Alvarez, Rita [1 ]
del Mar Garcia-Saiz, Maria [2 ,3 ,4 ]
机构
[1] Bioaraba Hlth Res Inst, Clin Trials Unit, Vitoria 01009, Spain
[2] Marques de Valdecilla Univ Hosp, Clin Pharmacol Serv, Santander 39008, Spain
[3] Univ Cantabria, Dept Physiol & Pharmacol, Santander 39012, Spain
[4] IDIVAL, Santander 39004, Spain
关键词
off-label prescription; immunosuppressive drugs; immunosuppressants; solid organ transplantation; clinical pharmacology;
D O I
10.3390/pharmacy12010017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Once a solid organ transplantation (SOT) has been performed, it is necessary to prescribe immunosuppressant medication to prevent graft rejection. This task has the peculiarity that many of these drugs do not have specific indications for transplant use in the technical data sheets. We performed a review of different immunosuppressive drugs' information available at European and American regulatory agencies in order to analyze the approved indications by the type of SOT. In our work, besides showing these differences between different indication approvals in different SOT modalities, we also attempted to reflect other differences under the approved indications according to age group, formulation type, geographical area, etc. Although consensus documents on the subject have been published, the access to immunosuppressants depends on each country's regulation and healthcare system, and off-label prescription is a reality that healthcare professionals need to be familiar with.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Off-Label Use of Drugs in Children
    Frattarelli, Daniel A. C.
    Galinkin, Jeffrey L.
    Green, Thomas P.
    Johnson, Timothy D.
    Neville, Kathleen A.
    Paul, Ian M.
    Van den Anker, John N.
    Knight, Matthew
    Alexander, John J.
    Kilpatrick, Sarah J.
    Cragan, Janet D.
    Rieder, Michael J.
    Robb, Adelaide S.
    Sachs, Hari
    Zajicek, Anne
    Haro, Tamar
    Koteras, Raymond K.
    Del Monte, Mark
    PEDIATRICS, 2014, 133 (03) : 563 - 567
  • [12] OFF-LABEL USES OF ANTICANCER DRUGS
    ABELOFF, MD
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (18): : 2473 - 2474
  • [13] Off-label uses of drugs in children
    Blumer, JL
    PEDIATRICS, 1999, 104 (03) : 598 - 602
  • [14] Off-label drugs in childhood psoriasis
    Mahe, E.
    Corgibet, F.
    Maccari, F.
    Hadj-Rabia, S.
    Phan, C.
    Ruer-Mulard, M.
    Boralevi, F.
    Barbarot, S.
    Bursztejn, A-C
    Lahfa, M.
    Severino-Freire, M.
    Aubin, F.
    Barthelemy, H.
    de la Breteque, M. Amy
    Beauchet, A.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2020, 147 (6-7): : 429 - 438
  • [15] Off-label use of antipsychotic drugs
    Hummer, M
    Koller, D
    Hofer, A
    Ulmer, H
    Fleischhacker, WW
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 161 - 161
  • [16] Off-label drugs for weight management
    Hendricks, Ed J.
    DIABETES METABOLIC SYNDROME AND OBESITY, 2017, 10 : 223 - 234
  • [17] Off-label use of prescription drugs
    Nightingale, SL
    AMERICAN FAMILY PHYSICIAN, 2003, 68 (03) : 425 - 427
  • [18] Off-label use of approved drugs
    DeVita, V. T., Jr.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (04) : 181 - 181
  • [19] Off-label use of approved drugs
    Vincent T. DeVita
    Nature Reviews Clinical Oncology, 2009, 6 : 181 - 181
  • [20] OFF-LABEL DRUGS AND SCIENTIFIC EVIDENCE
    Simon, C.
    Rebolledo Agueera, M.
    Marquez Rodriguez, P.
    Ferrer Artola, A.
    Vallano Ferraz, A.
    Arnau de Bolos, J. M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 111 : 19 - 19